Kornimate/medical-research-clean huggingface dataset:
using walk with ease walking program with men 65 and older being treated for prostate cancer

Conditions: Prostate Cancer

Summary: this study is testing a walking program called walk with ease by the arthritis foundation with men undergoing treatment for prostate cancer. the researchers are interested in how easy or difficult it is for these men to participate in this program and whether or not is is helpful to them during their care.

purpose: this pilot study evaluates the feasibility of implementing a moderate-intensity physical activity (pa) program in a sample of men age 65 or older with a prostate cancer diagnosis undergoing various forms of treatment or active surveillance. participants: men, 65 and older, with a prostate cancer diagnosis. procedures (methods): this study will enroll subjects in a 6 week walking program called walk with ease (wwe) and see if walking can be sustained for up to three months. in addition, the study will perform a geriatric assessment and gather preliminary data on self-reported quality of life outcomes and self-reported physical activity as captured in a daily walking log.

Eligibility criteria:
inclusion criteria: * ≥65 years of age * histologically confirmed stage i, ii or iii prostate cancer (endocrine (± radiation) patients may be stage iv) * undergoing prostate cancer treatment (post-surgery only, radiation only, endocrine therapy (± radiation), or active surveillance) * english speaking * irb approved, signed written informed consent * approval from their treating physician to engage in moderate-intensity physical activity * patient-assessed ability to walk and engage in moderate physical activity * willing and able to meet all study requirements exclusion criteria: * one or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention * major surgery scheduled within the study period * unable to walk or engage in moderate-intensity physical activity * already actively walking (150 minutes per week)

Keywords: prostate cancer elderly geriatric radiation arthritis exercise walking endocrine therapy androgen deprivation therapy active surveillance men
influence of tidal volume during mechanical ventilation on postoperative clinical outcome in pediatric patients undergoing congenital heart surgery

Conditions: Patients Who Underwent Surgery for Congenital Heart Disease

Summary: high tidal volume during mechanical ventilation has been reported to increase mortality in patients with acute lung injury or acute respiratory distress syndrome. high tidal volume was also reported to be associated with increased mortality in adult patients without acute lung injury or acute respiratory distress syndrome. however, the influence of high tidal volume on clinical outcome in pediatric patients who underwent surgery for congenital heart disease has not been evaluated yet. the investigators attempted to evaluate the effect of tidal volume on clinical outcome in both cyanotic and non-cyanotic congenital heart disease.

high tidal volume during mechanical ventilation has been reported to increase mortality in patients with acute lung injury or acute respiratory distress syndrome. high tidal volume was also reported to be associated with increased mortality in adult patients without acute lung injury or acute respiratory distress syndrome. however, the influence of high tidal volume on clinical outcome in pediatric patients who underwent surgery for congenital heart disease has not been evaluated yet. the investigators attempted to evaluate the effect of tidal volume on clinical outcome in both cyanotic and non-cyanotic congenital heart disease.

Eligibility criteria:
inclusion criteria: * pediatric patients who underwent surgery for congenital heart disease with cardiopulmonary bypass between 2009 and 2013 in samsung medical center exclusion criteria: * patients who lack data regarding mortality, creatinine, estimated glomerular filtration rate, or urine output.

Keywords: tidal volume congenital heart disease mortality
effects of replacing diet beverages with water on weight loss and plasma glucose control in type 2 diabetes

Conditions: Type 2 Diabetes; Overweight; Obese

Summary: the purpose of the present study is to evaluate the effect of replacing diet beverages with water on weight loss and biochemical indicators for insulin sensitivity and cardiometabolic risk factors of diabetic obese and overweight female adults when they are in a multidisciplinary weight loss plan.


Eligibility criteria:
inclusion criteria: * diabetic female patient with 6.5\<h1ac\<7.2. * monotherapy with metformin. * 18-45 years of age. * body mass index (bmi) between 27-35 kg/ m². * consume dbs regularly during their habitual diet. * must be able to have moderate exercise. * must be interested to have weight loss. exclusion criteria: * participating in a research project involving weight loss or physical activity in the previous six months. * pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * taking medication that could affect metabolism or change body weight. * report heart problems, chest pain, and cancer within the last five years. * unwilling to change intake of beverages during the study period.

Keywords: diet beverages water diabetes weight loss insulin sensitivity
observational safety and effectiveness study of adjuvanted swine origin a (h1n1) pandemic subunit egg derived vaccine

Conditions: Influenza A (H1N1)

Summary: this observational study will evaluate the safety and effectiveness following administration of adjuvanted swine origin a (h1n1) pandemic subunit egg derived vaccine through both an ad hoc active monitoring system and a passive surveillance of hospitalization in a large cohort.


Eligibility criteria:
inclusion criteria: * subjects resident in emilia-romagna and either registered with the ausl of reggio emilia, bologna, modena and parma or working in the province of reggio emilia, bologna, modena and parma included in the target groups described in the study protocol vaccination with h1n1sw vaccine focetria is recommended - according to the national pandemic plan adopted at the local level - will be eligible for enrolment. exclusion criteria: * subjects already vaccinated with another pandemic vaccine or with known contraindications to focetria, will be excluded from this study. * patients institutionalized in hospital, nursing homes, rehabilitation centers, as well as home-cared patients, will also be excluded.

Keywords: swine flu a (h1n1) vaccine adjuvanted flu egg derived novel influenza a (h1n1): a new flu virus of swine origin
validity and reliability of the turkish translation of the yale pharyngeal residue severity rating scale

Conditions: Swallowing Disorder; Validation; Pharyngeal Dysphagia

Summary: purpose of the study is the validity and reliability of the turkish version of the yale pharyngeal residue severity rating scale (yprsrs-t), so that it would be used as an assessment tool for dysphagia patients.

the swallow function is a multidirectional process that depends on complex neuro-muscular network. the function can be evaluated using instrumental, such as fibreoptic endoscopic evaluation of swallowing (fees), videofluoroscopy, or well structured scales. there are many questionnaire and scales for assessment of swallow but very few have been validated. the study will assess the construct validity and reliability of the turkish version of pharyngeal residue severity rating scale as known as yale pharyngeal residue severity rating scale.

Eligibility criteria:
inclusion criteria: * 18-70 years * at least having undergraduate education on health profession * agree to participant exclusion criteria: * out of age 18-70 years * out of having undergraduate education * mental disorder * cognitive limitations * visual limitations

Keywords: pharyngeal residue swallow scale yale
exploratory study of mri biomarkers of nash

Conditions: Non-alcoholic Fatty Liver Disease NAFLD

Summary: metabolic steatosis disease (nafld) is a rapidly growing disease in the world, particularly in industrialized countries. nafld is defined by the presence of fatty liver disease. this is a reversible phenomenon that can be estimated by non-invasive means, such as ultrasound. non-invasive quantification, on the other hand, requires mri. nonalcoholic steatohepatitis (nash) is the aggressive form of the disease that promotes the accumulation of fibrosis in the liver, which can progress to cirrhosis and its complications. currently there is no non-invasive biomarker of nash and the diagnosis is based solely on liver biopsy. there is therefore a need for non-invasive biomarkers of nash in patients with steatosis to diagnose nash without the use of liver biopsy.


Eligibility criteria:
inclusion criteria: * patient included in the sniff cohort of the angers hospital where there is a suspicion of nash requiring a biopsy for which an mri is requested by a hepatologist as part of the initial assessment of the disease. * adult patient * free, informed and express (oral) consent of the patient to participate in the study exclusion criteria: * contraindication to mri * time between the establishment of the steatosis/nash status and the mri greater than 3 months * pregnant, parturient and breastfeeding woman * person deprived of liberty by judicial or administrative decision * person under compulsion to psychiatric care * person subject to a legal protection measure * person not affiliated or not covered by a social security scheme.
an educational video to improve patient comprehension of midurethral sling

Conditions: Stress Urinary Incontinence; Knowledge, Attitudes, Practice

Summary: the purpose of this research project is to test the effectiveness of a previsit educational video designed to help women understand the risks and benefits of a midurethral sling for treatment of stress urinary incontinence. a total of 38 participants will be recruited from both the urogynecology pre-operative clinic of the university of california, irvine medical center and the urogynecology pre-operative clinic at kaiser permanente, anaheim and orange county. participants will be randomized either to watch a 10 minute educational video (intervention group) or read a standard handout describing the midurethral sling (control group). participants will then complete their pre-operative visit in the usual fashion. participants will complete a pre- and post- intervention knowledge questionnaire to assess the primary outcome (change in knowledge before and after intervention). participants will repeat the knowledge questionnaire and complete validated questionnaires for satisfaction with decision scale and decision regret at 2 and 6 weeks post-operative.


Eligibility criteria:
inclusion criteria: * women scheduled for a mid-urethral sling for stress urinary incontinence with a urogynecology provider at a participating hospital exclusion criteria: * \< 18 years of age * non-english speaking or requiring interpreter assistance * presence of cognitive dysfunction * women receiving a repeat midurethral sling (not primary) * women with a history of pelvic mesh complication (erosion, pain, history of mesh excision) * pregnant women
genetics of latent autoimmune diabetes in adults

Conditions: Latent Autoimmune Diabetes in Adult

Summary: this is a prospective study that will study adults and has the objective of examining 'latent autoimmune diabetes in adults' (lada) to understand how this trait is influenced by genetic factors.

a case-control study approach will be used to compare the allelic frequencies of deoxyribonucleic acid (dna) markers of the cases (i.e., lada patients) to a randomly selected control samples that does not have the trait under study. to study the role of genetic factors in lada, the study seeks to determine if certain genomic regions that are captured or mirrored by selective single nucleotide polymorphisms (snps) that are genotyped, are over or underrepresented in those with the disease compared to those who do not. the level of auto-antibodies is the serum can also be studied as a quantitative trait where we ask the question if there is correlation with specific snp alleles that are genotyped. the markers that are found to be over or under-represented in the study cases will then be tested in an independent set of patients also recruited in this study. this allows us to filter markers that show significance simply by chance and prevents us from being misled.

Eligibility criteria:
inclusion criteria: * diagnosed type 2 diabetes (t2d) patient with: bmi \ 25-\<50 at diagnosis or * diagnosed type 1 diabetes (t1d) patient with: age \>25 at diagnosis or - currently diagnosed with lada with age at initial diagnosis of diabetes \>25 years and a positive gad65 antibody test exclusion criteria: * any underlying disease or condition that is a contraindication for obtaining 18.0 ml of blood. * inability to obtain an informed consent from a given lada case. * blood sampling has already occurred for a given subject. * previous gad65 antibody test(s) negative.

Keywords: lada latent autoimmune diabetes in adults latent autoimmune diabetes latent diabetes in adults
facial type determination through cephalometry, anthropometry and facial analysis

Conditions: Healthy

Summary: introduction: human face with its bony and muscular structures has singular and peculiar characteristics. it may be classified in three types, associated with the variation of shape and craniofacial configuration, both in vertical and horizontal planes, directly affecting dental occlusion, face harmony, orofacial musculature and oral functions. aim: to correlate cephalometric with anthropometric and facial analysis findings on determining the facial type. method: 105 leukoderm adults were involved, 34 male and 71 female aging between 20 and 40 years old. data were collected in december 2006 in an orthodontic clinic located at belo horizonte- mg, brazil. cephalometric findings to determinate facial types were compared to seven anthropometric facial measurements, three anthropometric facial proportions and three anthropometric facial indices, in addition to facial type identification through clinical facial analysis of photographs.


Eligibility criteria:
inclusion criteria: * to have ricketts cephalometric analysis exclusion criteria: * to have been submitted on orthognathic surgery * black or asian people

Keywords: face cephalometry anthropometry photography diagnosis adult morphology comparative study
relation of catechol-o-methyltransferase (comt) genotype and response to cognitive remediation schizophrenia

Conditions: Chronic Schizophrenia

Summary: this project will explore the relationship between catechol-o-methyltransferase (comt) val158/108met genotype and response to a 12-week computerized neurocognitive rehabilitation (crt) given to chronic schizophrenic patients.

cognitive deficits play a crucial role in both the pathogenesis and prognosis of schizophrenia. the comt gene is functionally expressed in neural systems considered important in a range of healthy brain functions and brain disorders, including schizophrenia. the comt met allele has been shown to be associated with a lower activity form of comt, and with better performance on neurocognitive tests, while the comt val allele is associated with poorer executive cognition. this study will investigate the relationship of comt polymorphism in patients with chronic schizophrenia with the response to crt targeting visuospatial processing, attention, and cognitive flexibility using matrics consensus cognitive battery (mccb) developed by the nih-matrics initiative.

Eligibility criteria:
inclusion criteria: 1. participation in the active arm of the neurocognitive remediation program 2. age 18 - 55 3. inpatients 4. dsm-iv diagnosis of schizophrenia (all subtypes) with illness duration \>5 years 5. auditory and visual acuity adequate to complete cognitive tests 6. stable dose of oral atypical antipsychotic for at least 4 weeks 7. total panss score \> 60 8. rbans total score ≤ 80 9. mmse score of greater than or equal to 24 10. good physical health determined by physical examination, laboratory tests 11. capacity and willingness to give written informed consent exclusion criteria: 1. inability to read or speak english 2. documented disease of the central nervous system 3. history of intellectual impairment pre-dating onset of symptoms of psychosis (e.g. mental retardation) 4. clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal, pulmonary or hematologic conditions 5. hiv + 6. patients diagnosed with substance dependence 7. currently participating in another experimental study, except for the parent study.
a study of the safety and effectiveness of infliximab (remicade) in patients with juvenile rheumatoid arthritis

Conditions: Rheumatoid Arthritis, Juvenile

Summary: the purpose of this study is to evaluate the effectiveness and safety of infliximab (remicade) in patients with juvenile rheumatoid arthritis (jra).

the purpose of this study is to determine if infliximab in combination with methotrexate is safe and effective in the treatment of patients with juvenile rheumatoid arthritis. the second purpose of this study is to see how children's bodies react to the combination of study drug and methotrexate. patients will receive either infliximab at 3 mg/kg for 44 weeks or, placebo for 14 weeks followed by infliximab at 6 mg/kg for 30 weeks. patients who complete the original study are eligible for additional treatment with 3 to 6 mg/kg of infliximab every 8 weeks for up to three years. safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. patients will receive either infliximab at 3 mg/kg for 44 weeks or, placebo for 14 weeks followed by infliximab at 6 mg/kg for 30 weeks. patients who complete the original study are eligible for additional treatment with 3 to 6 mg/kg of infliximab every 8 weeks for up to three years

Eligibility criteria:
inclusion criteria: * patients must have a diagnosis of juvenile rheumatoid arthritis (jra) with polyarticular jra for at least 6 months, systemic jra with a polyarticular course and no systemic symptoms (including fever, rash,hepatosplenomegaly, and serositis) for 1 year prior to study entry, or pauciarticular jra with a polyarticular course for at least 6 months prior to study entry. the patient should have had at least 6 months of persistent synovitis before screening. * the patient must have at least 5 joints with active arthritis (ie, presence of swelling, or if no swelling is present, limitation of motion accompanied by pain, tenderness, or both) at the time of enrollment, with at least 3 of these active joints having limitation of motion accompanied by pain, tenderness, or both * the patient must be at least 4 years of age, but less than 18 years (ie, after the 4th but before the 18th birthday), with onset of disease before age 16. exclusion criteria: * patient must not be pregnant, nursing, or planning a pregnancy within 6 months after the last study infusion * patient must not be incapacitated, largely or wholly bedridden, or confined to a wheelchair, or have little or no ability for age-appropriate self care * patient must not have a rheumatic disease other than jra or any current systemic inflammatory condition (for example, lyme disease,fibromyalgia, enthesitis-related arthritis, psoriatic arthritis, systemic lupus erythematosus, infectious or reactive arthritis, reiter's syndrome, or parvovirus infection)

Keywords: juvenile rheumatoid arthritis infliximab methotrexate remicade
study to evaluate nilotinib in chronic myelogenous leukemia (cml) patients with suboptimal response

Conditions: Philadelphia Chromosome Positive; Chronic Myelogenous Leukemia in Chronic Phase

Summary: to evaluate the major molecular response (mmr) rate at 12 months of nilotinib treatment on study in patients with philadelphia chromosome positive (ph+) chronic myelogenous leukemia in chronic phase (cml-cp) who have a suboptimal molecular response to imatinib at 18 months or later.


Eligibility criteria:
inclusion criteria: 1. male or female patients ≥ 18 years of age. 2. ecog 0, 1, or 2. 3. have been diagnosed with ph+ cml-cp and receiving imatinib therapy. 4. patients with suboptimal molecular response to imatinib treatment continued for at least 18 months (first line therapy) suboptimal molecular response defined as all of the following conditions: 1. patients who have achieved ccyr (0% ph+ chromosomes). 2. patients who don't achieve mmr (mmr defined as bcr-abl/abl ratio of ≤ 0.1% on the international scale as detected by rq-pcr). the treatment with imatinib defined as: dose of 300 mg or higher daily must be maintained for a minimum of 3 months prior to study entry. 5. patients who meet the following laboratory tests criteria: 1. total bilirubin \< 1.5 x uln, 2. sgot and sgpt \< 2.5 x uln, 3. creatinine \< 1.5 x uln, 4. serum amylase and lipase ≤ 1.5 x uln, 5. alkaline phosphatase ≤ 2.5 x uln unless considered tumor related. 6. serum potassium, phosphorus, magnesium and calcium ≥ lln or correctable with supplements prior to the first dose of study drug. 6. written informed consent prior to any study related screening procedures being performed. exclusion criteria: 1. prior accelerated phase or blast crisis cml. 2. previously documented t315i mutations. 3. presence of chromosomal abnormalities other than ph+. 4. previous treatment with any other tyrosine kinase inhibitor except imatinib. 5. impaired cardiac function including any one of the following: 1. complete left bundle branch block 2. congenital long qt syndrome or family history of long qt syndrome 3. history of or presence of significant ventricular or atrial tachyarrhythmias 4. clinically significant resting brachycardia (\<50 bpm) 5. qtcf \> 450 msec on screening ecg 6. use of a ventricular-paced pacemaker 7. myocardial infarction during the last 12 months 8. other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina). 6. treatment with strong cyp3a4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, st john's wort), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. see section 6.4.3 for complete list of these medications.

Keywords: chronic phase chronic myelogenous leukemia cml philadelphia chromosome positive ph+ nilotinib cml-cp suboptimal molecular response